Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell vaccine + psma peptide + klh
- Development stage
- Unknown
- Lead developer
- QIMR Berghofer Medical Research Institute
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Autologous dendritic cell vaccine + psma peptide + klh is an investigational cancer immunotherapy developed by the Queensland Institute of Medical Research (QIMR) for the treatment of hormone-refractory (castration-resistant) prostate cancer. The vaccine is composed of a patient's own dendritic cells, which are harvested and loaded ex vivo with synthetic peptides derived from the Prostate-Specific Membrane Antigen (PSMA). Keyhole Limpet Haemocyanin (KLH) is included as a helper antigen to enhance the overall immunogenicity of the vaccine. Once re-administered to the patient, these primed dendritic cells present PSMA antigens to the immune system, specifically activating T-cells to recognize and eliminate prostate cancer cells that overexpress PSMA.
- Other names
- PSMA-pulsed dendritic cell vaccinedendritic cell PSMA peptide vaccinePSMA-DC vaccineautologous dendritic cell vaccine + psma peptide + klh
02
Targets
HLA-DR (Human leukocyte antigen DR)PSMA (Prostate-specific membrane antigen)MHC I (MHC class I})
Beyond the preview
Go deeper on autologous dendritic cell vaccine + psma peptide + klh.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell vaccine + psma peptide + klh.